Charles River Laboratories to Acquire the CRO Services Division of Galapagos NV - Pharmaceutical Technology

Latest Issue
PharmTech

Latest Issue
PharmTech Europe

Charles River Laboratories to Acquire the CRO Services Division of Galapagos NV



Charles River Laboratories has entered into an agreement to acquire the CRO services division of Galapagos NV, which includes both Argenta and BioFocus. These businesses offer integrated drug discovery services, with a focus on in-vitro capabilities. The acquisition will help position Charles River as a full service, early-stage CRO, with integrated in-vitro and in-vivo capabilities from target discovery through preclinical development. The purchase price is €129 million (approximately $179 million), and the transaction includes future performance payments of up to €5 million (approximately $7 million).
 
Located in the United Kingdom and the Netherlands, Argenta and BioFocus provide a full suite of drug discovery services from target discovery through the delivery of clinic-ready candidates to a broad range of pharmaceutical and biotechnology companies.

Source: Charles River Laboratories

ADVERTISEMENT

blog comments powered by Disqus
LCGC E-mail Newsletters

Subscribe: Click to learn more about the newsletter
| Weekly
| Monthly
|Monthly
| Weekly

Survey
What role should the US government play in the current Ebola outbreak?
Finance development of drugs to treat/prevent disease.
Oversee medical treatment of patients in the US.
Provide treatment for patients globally.
All of the above.
No government involvement in patient treatment or drug development.
Finance development of drugs to treat/prevent disease.
30%
Oversee medical treatment of patients in the US.
9%
Provide treatment for patients globally.
8%
All of the above.
45%
No government involvement in patient treatment or drug development.
8%
Jim Miller Outsourcing Outlook Jim MillerCMO Industry Thins Out
Cynthia Challener, PhD Ingredients Insider Cynthia ChallenerFluorination Remains Key Challenge in API Synthesis
Marilyn E. Morris Guest EditorialMarilyn E. MorrisBolstering Graduate Education and Research Programs
Jill Wechsler Regulatory Watch Jill Wechsler Biopharma Manufacturers Respond to Ebola Crisis
Sean Milmo European Regulatory WatchSean MilmoHarmonizing Marketing Approval of Generic Drugs in Europe
Legislators Urge Added Incentives for Ebola Drug Development
FDA Reorganization to Promote Drug Quality
FDA Readies Quality Metrics Measures
New FDA Team to Spur Modern Drug Manufacturing
From Generics to Supergenerics

Click here